Attached files

file filename
EX-31.2 - EXHIBIT 31.2 - Protagenic Therapeutics, Inc.\newv393503_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - Protagenic Therapeutics, Inc.\newv393503_ex31-1.htm
EXCEL - IDEA: XBRL DOCUMENT - Protagenic Therapeutics, Inc.\newFinancial_Report.xls
10-Q - QUARTERLY REPORT - Protagenic Therapeutics, Inc.\newv393503_10q.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Atrinsic, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Edward Gildea, Chief Executive Officer, and David Horin, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

Date: November 13, 2014      By: /s/ Edward Gildea
    Edward Gildea
    Chief Executive Officer
    (Principal Executive Officer)

 

Date: November 13, 2014      By: /s/ David Horin
    David Horin
    Chief Financial Officer
    (Principal Executive Officer)